We also observed that Hsp90 inhibitor ganetespib improved 177Lu-octreotate therapy synergistically in vivo and that the potentiation of radiation-induced tumour-killing persisted ex vivo in SINET patient-derived tumour cells. Here, HSP90AA1 is linked to neoplasm.